Genital Herpes Immunotherapy GEN-003 Shows Sustained Reduction of Viral Shedding Rate, Durable Impact on Clinical Disease 12 ...
- Consistent efficacy across potential Phase 3 clinical trial endpoints - - Once-yearly or less frequent maintenance dosing expected - - Company to host conference call at 9 a.m. ET today - CAMBRIDGE, Mass., March 31, 2016 (GLOBE NEWSWIRE) -- Genocea …